Advanced Filters
noise

Vaccines Clinical Trials

A listing of Vaccines medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 506 clinical trials
A Ahmed IDBAIH, MD, PhD

New Adjuvant Vaccine in Glioblastoma, a Phase 1/2a Study

This phase I/II trial evaluates the safety and the immunological efficacy of a cancer vaccine against 2 glioma-associated antigens in newly-diagnosed glioblastomas. The objectives of this study are as follows: Primary objective phase 1: to assess the maximum tolerated dose (MTD) and select the recommend Phase 2a dose phase 2a: …

18 - 75 years of age All Phase 1/2
L Laura H Kwong, PhD

Vaccine Confidence and Infodemic in Southeast Asia's Nusantara Sociocultural Sphere

The goal of this clinical trial is to understand how well a culturally-specific "prebunking" video can improve vaccine information literacy and vaccine confidence among individuals in the Nusantara sociocultural sphere. The investigators hypothesize the individuals who watch the co-created "prebunking" intervention video will have improved vaccine literacy skills and vaccine …

18 years of age All Phase N/A

Autologous Dendritic Cell Vaccine For Recurrent Respiratory Papillomatosis (RRP) Patients

The purpose of this study is to evaluate the safety and immunogenicity of autologous DC vaccine in recurrent respiratory papillomatosis patients

18 years of age All Phase 1
H Helmut Salih, Prof. Dr.

FusionVAC22_01: Fusion Transcript-based Peptide Vaccine Combined with Immune Checkpoint Inhibition

The aim of this clinical trial is to evaluate the immunogenicity along with safety and toxicity as well as first efficacy of a DNAJB1-PRKACA fusion transcript-based peptide vaccine (Fusion-VAC-XS15) in combination with anti-programmed cell death-ligand 1 immune checkpoint inhibition (ICI) by Atezolizumab (TecentriqTM) in patients with Fibrolamellar hepatocellular carcinoma (FL-HCC) …

18 years of age All Phase 1
J Jeannine M Haller, RN, CCRP

Phase 2 Safety and Immunogenicity Study of Rift Valley Fever Vaccine

This study is to collect safety and immunogenicity data for an Rift Valley Fever (RVF) vaccine

18 - 65 years of age All Phase 2

COVID-2019 Vaccine Immune Response Base on Single Cell Multi-Omics

In recent years, single-cell high-throughput sequencing technology has developed rapidly and is widely used in research related to the immune system, breaking traditional cognition and gaining a new understanding of immune cell classification. In particular, the emerging single cell RNA sequencing (scRNA-seq) provides new ideas for the study of cell …

18 - 50 years of age All Phase N/A
X Xingchen Peng, Ph.D

Intranasal WSK-IM05 Vaccine Plus Tislelizumab as Neoadjuvant Therapy for HPV+ OPSCC

This phase I, open-label, single-arm trial uses a "3+3" dose-escalation design to evaluate the safety, tolerability, and preliminary efffcacy of intranasal WSK-IM05 vaccine combined with tislelizumab as neoadjuvant therapy in patients with resectable HPV-positive oropharyngeal squamous cell carcinoma. Participants receive two cycles of WSK-IM05 (intranasal) and tislelizumab (200 mg IV) …

18 years of age All Phase 1
V VRC Clinic

Safety and Immunogenicity of Ad4-HIV Envelope Vaccine Vectors in Healthy Volunteers

Background Researchers want see if three new HIV (human immunodeficiency virus) vaccines are safe. Two vaccines are carried by live adenoviruses, which are natural and typically cause cold symptoms or an eye infection. Researchers want to see if all the vaccines help fight HIV and if the adenoviruses are contagious. …

18 - 65 years of age All Phase 1

ID93+GLA-SE Vaccine Against Tuberculosis in Older Adults Aged 55-74

The purpose of this study is to evaluate the safety and explore the immunogenicity of ID93+GLA-SE compared to placebo following three intramuscular (IM) injections on Days 0, 28 and 56 in the Bacillus Calmette-Guérin (BCG)-vaccinated older adults aged 55 to 74 with negative or positive result on the QuantiFERON-TB (QFT) …

55 - 74 years of age All Phase 1
F Fausto Baldanti

Immunogenicity, Efficacy and Safety of Recombinant Herpes Zoster Vaccine in Frail Patients

Herpes zoster (HZ) is a serious health problem whose incidence and severity increase with the decline of cell-mediated immunity (CMI) because of age and immunocompromised (IC) status. Subclinical reactivation are described and may boost the adaptive specific immunity. T cells play a major role in preventing reactivation of Varicella Zoster …

years of age All Phase N/A

Simplify language using AI